QUÉBEC CITY, Feb. 22 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced that its Vice President, Alliance Management and Intellectual Property, Eckhard Guenther, Ph.D., will make a presentation on two of the Company’s novel anticancer compounds, AEZS-108 and AEZS-129, at Bio Partnering North America on Monday, February 28, 2011, at 4 p.m. (Pacific Time) in the West Meeting Room 218, of the Vancouver Convention Center in Vancouver, Canada.
AEZS-108, the LHRH targeted cytotoxic peptide conjugate composed of a peptide carrier and a cytotoxic agent (doxorubicin), has successfully completed a Phase 2 program in advanced ovarian and advanced endometrial cancer. This compound is also currently in Phase 1/2 trials in refractory prostate cancer and bladder cancer. AEZS-129, an orally-active PI3K inhibitor compound, is in preclinical development in oncology.
Furthermore, Company President and CEO, Juergen Engel, Ph.D., will take part in a panel discussion on novel cancer treatments at the upcoming RBC Capital Markets Healthcare Conference. The panel discussion entitled, “Cancer Treatments: Under the Radar Unique Late-Stage Opportunities”, will take place on Wednesday, March 2, 2011, at 9 a.m. (Eastern Time) in the Holmes I Room of the New York Palace Hotel, in New York City.
A live audio webcast of the panel discussion will be available on Aeterna Zentaris’ website at www.aezsinc.com, in the Newsroom section. A replay of the webcast will also be available on the Company’s website for a period of 90 days.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, ovarian, endometrial cancer and multiple myeloma. The Company’s innovative approach of “personalized medicine” means tailoring treatments to a patient’s specific condition and to unmet medical needs. Aeterna Zentaris’ deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.
